Advantage

Main information

  • Trade name:
  • Advantage 40 Feline and Bunny Spot-on Solution
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Advantage 40 Feline and Bunny Spot-on Solution
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • imidacloprid
  • Therapeutic area:
  • Cats, Rabbit

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0389/001
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0389/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:01256/2010

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Advantage40mgfelineandbunnySpot-onsolution[UK]

Advantage40mgSpot-onsolutionforSmallCatsandSmallPetRabbits[AT,DE,FR,

IE,IT]

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each0.4mlpipettecontains:

Activesubstance:

Imidacloprid 40mg

Excipient(s):

Butylhydroxytoluene(E321) 0.4mg

Benzylalcohol 332.8mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution

Clearyellowtoslightlybrownishsolution

4. CLINICALPARTICULARS

4.1Targetspecies

Catsandpetrabbits

4.2Indicationsforuse,specifyingthetargetspecies

Forcatsoflessthan4kg:

Preventionandtreatmentoffleainfestations

Forpetrabbitsoflessthan4kg:

Treatmentoffleainfestations

Fleasarekilledwithinonedayfollowingtreatment.Onetreatmentpreventsfurtherflea

infestationforthreetofourweeksoncatsanduptooneweekonpetrabbits.The

productcanbeusedaspartofatreatmentstrategyforthecontrolofFleaAllergy

Dermatitis(FAD)incats,wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

Issued:December2011

AN:01256/2010

Page2of7

4.3Contraindications

Donottreatunweanedkittensoflessthan8weeksofage.

Donotuseonrabbitsintendedforhumanconsumption.

Donotuseonpetrabbitsoflessthan10weeksofage.

Donotuseinanimalsthatareknowntobehypersensitivetotheactivesubstanceorany

oftheexcipients.

4.4Specialwarnings

Re-infestationfromemergenceofnewfleasintheenvironmentmaycontinuetooccurfor

sixweeksorlongeraftertreatmentisinitiated.Morethanonetreatmentmaytherefore

berequired,dependingontheleveloffleasintheenvironment.Toaidreductionin

environmentalchallenge,theadditionaluseofasuitableenvironmentaltreatment

againstadultfleasandtheirdevelopingstagesisrecommended.Inordertoreduce

furthertheenvironmentalchallenge,itisrecommendedthatalldogs,catsandrabbitsin

thehouseholdaretreated.Treatmentofnursingqueensanddoescontrolsflea

infestationsonbothdamandoffspring.

Theproductremainseffectiveiftheanimalbecomeswet,forexampleafterexposureto

heavyrain.However,re-treatmentmaybecomenecessary,dependingonthepresence

offleasintheenvironment.Inthesecasesdonottreatmorefrequentlythanonceweekly.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thisproductisfortopicaluseandshouldnotbeadministeredorally.

Applyonlytoundamagedskin

Careshouldbetakentoavoidthecontentsofthepipettecomingintocontactwiththe

eyesormouthoftherecipientanimal.

Donotallowrecentlytreatedanimalstogroomeachother.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsthoroughlyafteruse.

Washoffanyskincontaminationwithsoapandwater.

Peoplewithknownskinsensitivitymaybeparticularlysensitivetothisproduct.

Avoidcontactoftheproductwiththeeyesormouth.

Iftheproductgetsintoeyesaccidentally,theeyesshouldbethoroughlyflushedwith

water.Ifskinoreyeirritationpersists,ortheproductisaccidentallyswallowed,obtain

medicalattention.

Donoteat,drinkorsmokeduringapplication.

Issued:December2011

AN:01256/2010

Page3of7

4.6Adversereactions(frequencyandseriousness)

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationanddisap-

pearswithinsomeminuteswithouttreatment(seealsosection4.9Amountstobe

administeredandadministrationroute).

Inveryrareoccasionsskinreactionssuchashairloss,redness,itchingandskinlesions

mayoccurincatsandrabbits.Agitation, excessivesalivationandnervoussignssuchas

incoordination,tremorsanddepressionhavealsobeenreportedbutexceptionallyin

cats.

4.7Useduringpregnancy,lactationorlay

Sincenoprimaryembryotoxic,teratogenicorreproductivetoxiceffectshavebeen

observedduringthestudieswithimidaclopridonratsandrabbitstheproductcanbe

usedinpregnantorlactatingdoes.Studiesonpregnantandlactatingqueenstogether

withtheiroffspringarelimited.Evidencesofarsuggeststhatnoadverseeffectsareto

beexpectedintheseanimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noincompatibilityhasbeenobservedbetweenthisproductattwicetherecommended

doseandthefollowingcommonlyusedveterinaryproducts:lufenuron,pyranteland

praziquantel(cats).Thecompatibilityoftheproductwasalsodemonstratedwithawide

rangeofroutinetreatmentsunderfieldconditionsincludingvaccination.

4.9Amountstobeadministeredandadministrationroute

DosageandTreatmentSchedule

Cat/Rabbit(kgbw) Product Numberof

Pipettes Imidacloprid

(mg/kgbw)

<4kg Advantage40forSmall

CatsandSmallPet

Rabbits 1x0.4ml minimumof10

MethodofAdministration

Removeonepipettefromthepackage.Holdpipetteinanuprightposition,twistandpull

offcap.Usereversedcaptotwistandremovesealfrompipette.

Issued:December2011

AN:01256/2010

Page4of7

AdministrationtotheCat

Partthehaironthecat'sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthepipetteontheskinandsqueezefirmlyseveraltimestoemptythecontents

directlyontotheskin.

AdministrationtotheRabbit

Partthehairontherabbit’sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthetubeontheskinandsqueezefirmlyseveraltimestoemptythecontentsdirectly

ontotheskin.

AllSpecies

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationand

disappearswithinsomeminuteswithouttreatment.Applicationatthebaseoftheskull

willminimizetheopportunityforthecattolicktheproduct.

Applyonlytoundamagedskin.Donotallowrecentlytreatedanimalstogroomeach

other.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incats,noadverseclinicalsignswereproducedusingdosesoffivetimesthe

therapeuticlevelweeklyforeightconsecutiveweeks.

Inrabbits,noadverseclinicalsignswereseenusingdosesofupto45mg/kgbody

weight(4timesthetherapeuticlevel)weeklyfor4consecutiveweeks.

Issued:December2011

AN:01256/2010

Page5of7

Inrarecasesofoverdoseorlickingoftreatedfur,nervoussystemdisorders(suchas

twitching,tremors,ataxia,mydriasis,miosis,lethargy)canoccurincats.

Poisoningfollowinginadvertentoraluptakeinanimalsisunlikely.Inthisevent,treatment

shouldbesymptomaticunderveterinarymedicalattention.Thereisnoknownspecific

antidotebutadministrationofactivatedcharcoalmaybebeneficial.

4.11Withdrawalperiod(s)

Donotuseonrabbitsintendedforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:antiparasiticagent

ATCvetcode:QP53AX17

5.1Pharmacodynamicproperties

Imidacloprid,1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamineisan

ectoparasiticidebelongingtoagroupofchloronicotinylcompounds.Chemically,itis

moreaccuratelydescribedasachloronicotinylnitroguanidine.

Thesubstancehasahighaffinityforthenicotinergicacetylcholinereceptorsinthepost-

synapticregionofthecentralnervoussystem(CNS).Theensuinginhibitionof

cholinergictransmissionininsectsresultsinparalysisanddeath.Duetotheweak

natureoftheinteractionwithmammaliannicotinergicreceptorsitesandthepostulated

poorpenetrationthroughtheblood/brainbarrierinmammals,ithasvirtuallynoeffecton

themammalianCNS.Theminimalpharmacologicalactivityinmammalsissupportedby

safetystudiesinvolvingsystemicadministrationofsub-lethaldosestorabbits,miceand

rats.

Infurtherstudies,inadditiontotheadulticidefleaefficacyofimidacloprid,alarvicidal

fleaefficacyinthesurroundingsofthetreatedpethasbeendemonstrated.Larval

stagesinthepet’ssurroundingsarekilledfollowingcontactwithatreatedanimal.

5.2Pharmacokineticparticulars

Theproductisindicatedforcutaneousadministration.Followingtopicalapplicationin

cats,thesolutionisquicklydistributedovertheanimal.Acutedermalstudiesintherat

andtargetanimaloverdoseandserumkineticstudieshaveestablishedthatsystemic

absorptionisverylow,transientandnotrelevantfortheclinicalefficacy.Thishasbeen

furtherdemonstratedbyastudyinwhichfleaswerenotkilledafterhavingfedon

previouslytreatedanimalsoncetheanimal’sskinandfurhadbeencleanedofallactive

material.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxytolueneE321

Issued:December2011

AN:01256/2010

Page6of7

Benzylalcohol

Propylenecarbonate

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:

5years

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Keeptheblisterintheoutercarton.

6.5Natureandcompositionofimmediatepackaging

Packsizes 0.4mlsolutionperpipette

Blisterpackcontaining2,3,4,or6unitdosepipettes

Container Whitepolypropylenepipetteswithcaps

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

Bayerplc

AnimalHealthDivision

BayerHouse

StrawberryHill

Newbury

Berkshire

RG141JA

8. MARKETINGAUTHORISATIONNUMBER

Vm00010/4177

Issued:December2011

AN:01256/2010

Page7of7

9. DATEOFFIRSTAUTHORISATION

8December2011

10.DATEOFREVISIONOFTHETEXT

December2011

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

28-11-2018

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

Health Canada

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

12-10-2018

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA - U.S. Food and Drug Administration

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

20-8-2018

Danish Medicines Agency lands new European chairmanship

Danish Medicines Agency lands new European chairmanship

Nikolai Brun, Director of Medical Evaluation & Biostatistics, has been elected chair of the Task Force on Big Data in the pharmaceutical area. The task force is a collaboration between the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) which is to identify advantages and challenges of using big data for the development of medicine.

Danish Medicines Agency

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

6-8-2018

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling 30 1-lb containers of Pat's Cat Turkey Cat Food and 40 2-lb containers of Ground Lamb Dog Food because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes can cause serious and sometimes fatal infections in animals eating the products.

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

12-6-2018

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

The lamp has incorrect lightbulb wattage information printed on a label on the sockets of the lamp. The incorrect labels indicate that each socket can support 40 W bulbs, however the product is only rated for each socket supporting a 25 W bulb. The use of lightbulbs with the incorrect wattage could potentially melt the power-switch, posing a burn hazard.

Health Canada

3-5-2018

FDA Approves Application for AquaBounty Salmon Facility in Indiana

FDA Approves Application for AquaBounty Salmon Facility in Indiana

FDA approved a supplemental New Animal Drug Application submitted by AquaBounty Technologies, Inc. The supplemental NADA requested FDA approval to raise AquAdvantage Salmon at a land-based contained facility near Albany, Indiana.

FDA - U.S. Food and Drug Administration

6-4-2018

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

Health Canada is advising Canadians that one lot of “Organic Traditions Shatavari Powder” is being voluntarily recalled by Advantage Health Matters Inc. Company testing found Salmonella bacteria contamination, which may pose serious health risks. According to Advantage Health Matters Inc., 13 units from the affected lot were distributed. Of the 13 units, only 2 packages, sold at Choices Markets Yaletown (1202 Richards Street) in Vancouver, B.C., have not been recovered.

Health Canada

27-8-2018

Beromun (BELPHARMA s.a.)

Beromun (BELPHARMA s.a.)

Beromun (Active substance: Tasonermin (Tumor Necrosis Factor alfa-1a)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5699 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/206/T/40

Europe -DG Health and Food Safety

7-8-2018

ACMD meeting statement, Meeting 40, 12 April 2018

ACMD meeting statement, Meeting 40, 12 April 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

11-6-2018

Zydelig (Gilead Sciences Ireland UC)

Zydelig (Gilead Sciences Ireland UC)

Zydelig (Active substance: idelalisib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3765 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3843/T/40

Europe -DG Health and Food Safety

28-5-2018

Seresto and its associated name Foresto

Seresto and its associated name Foresto

Seresto and its associated name Foresto (Active substance: imidacloprid/flumethrin) - Community Referrals - Art 13 - Commission Decision (2018)3404 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/125

Europe -DG Health and Food Safety

16-5-2018

Elonva (Merck Sharp and Dohme B.V.)

Elonva (Merck Sharp and Dohme B.V.)

Elonva (Active substance: corifollitropin alfa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3049 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1106/T/40

Europe -DG Health and Food Safety